Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 7/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.36 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633055 | 0.89 | NAMPT (0.38) | AGPAT2NAMPTHDAC8HDAC6TMPRSS2 | |
| SCHEMBL19636657 | 0.86 | DRD2 (0.38) | NAMPT | |
| SCHEMBL20796305 | 0.79 | KMT2A (0.42) | NAMPTMEN1KMT2ALMNA | |
| SCHEMBL19633219 | 0.78 | AGPAT2 (0.40) | AGPAT2NAMPTMEN1KMT2AKDM4E | |
| SCHEMBL19614928 | 0.72 | NAMPT (0.42) | NAMPTHDAC8HDAC6AR | |
| Hydrochloric Acid SCHEMBL30944564 | 0.70 | MEN1 (0.41) | AGPAT2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL19614874 | 0.69 | ITGB3 (0.47) | MEN1KMT2A | |
| SCHEMBL3984841 | 0.69 | MEN1 (0.43) | AGPAT2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7116824 | 0.69 | TGM2 (0.54) | AGPAT2MEN1KMT2ALMNA | |
| SCHEMBL30944502 | 0.68 | NAMPT (0.42) | AGPAT2NAMPTMEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | AGPAT2 4249/4885NAMPT 3033/4885HDAC8 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.